Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.

Abstract

BACKGROUND:

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations.

OBJECTIVES:

To report the long-term (2·5-year) efficacy and safety of secukinumab in nail psoriasis.

METHODS:

TRANSFIGURE, a double-blind, randomized, placebo-controlled, parallel-group, multicentre phase IIIb study in 198 patients, investigated secukinumab 150 mg and 300 mg in patients with moderate-to-severe nail psoriasis.

RESULTS:

At week 16, the primary endpoint Nail Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2·5 years with a large benefit for nail clearance, with mean NAPSI improvement of -73·3% and -63·6% with secukinumab 300 mg and 150 mg, respectively. At 2·5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) quality-of-life (QoL) scores of -52·4% and -18·1%, and 70% and 71% of patients achieved a weighted NAPPA Patient Benefit Index global score of ≥ 2 with secukinumab 300 mg and 150 mg, respectively. Patients showed considerable improvements in the EuroQol 5-Dimension health status questionnaire at 2·5 years, reporting a decrease in pain and discomfort. No new safety findings were observed.

CONCLUSIONS:

Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.

• Authors: K Reich, J Sullivan, P Arenberger, S Jazayeri, U Mrowietz, M Augustin, B Elewski, R You, P Regnault, J A Frueh
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 184 Issue 3 Pg. 425-436 (03 2021) ISSN: 1365-2133 [Electronic] England
• PMID: 32479641 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 British Association of Dermatologists.

Chemical References

• Antibodies, Monoclonal, Humanized
• secukinumab

Topics

• Antibodies, Monoclonal, Humanized
• Double-Blind Method
• Humans
• Psoriasis (drug therapy)
• Quality of Life
• Severity of Illness Index
• Treatment Outcome